Özet:

Goal: Glioblastoma Multiforme (GBM) is the most common primary malignant brain tumor in adults. The optimal treatment is adjuvant simultaneous chemoradiotherapy and then adjuvant chemotherapy after the broadest possible surgical resection (maximum safe resection). However, the geriatric group is not optimally treated. Recent studies have shown that, like young patients, optimal treatment is beneficial in the elderly group. We also aimed at exploring the effects of optimal treatment on survival in patients aged 65 and over. Methods: Documents of 71 patients with GBM pathological diagnosis followed between 2010-2018 in the Medical Oncology Clinic of the Pamukkale University School of Medicine were evaluated as retrospective. The demographic and clinical characteristics of patients were recorded from the file Results: 25 of the 71 patients assessed (35.2%) were 65 years old and older, 46 (64.8%) were under 65 years old. Of the twenty-five patients, 11 (44 percent) were men and 14 (56 percent) women. In the entire patient group, the average follow-up period was 16.2 months (12.4-19.9), the average overall survival period was 12.5 months (10.4-14.7 months). The average overall survival of patients under the age of sixteen and fifty was 15.1 months (12.6-17.6 months), while patients aged 65 and older were 8.6 months (7.9-9.3 months) (p<0.001). The average overall survival of patients aged 65 and older who received optimal treatment was 8.9 months (8.4-9.4 months), while the average overall survival of patients who did not receive treatment was 7.9 months (3.4-12.4 months) (p:0.048). The result: patients aged 65 and older who received optimal treatment were significantly longer than those who had no overall survival period. It has been shown that when older patients with good performance are able to get optimal treatment as young patients, survival results are improved.

Anahtar Kelimeler: